A detailed history of Woodstock Corp transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Woodstock Corp holds 180,806 shares of ALDX stock, worth $857,020. This represents 0.09% of its overall portfolio holdings.

Number of Shares
180,806
Previous 180,806 -0.0%
Holding current value
$857,020
Previous $598,000 62.88%
% of portfolio
0.09%
Previous 0.06%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 08, 2024

BUY
$3.25 - $4.72 $32,795 - $47,629
10,091 Added 5.91%
180,806 $598,000
Q1 2024

Apr 09, 2024

BUY
$2.77 - $4.22 $149,610 - $227,926
54,011 Added 46.28%
170,715 $558,000
Q4 2023

Jan 08, 2024

SELL
$1.47 - $6.06 $30,098 - $124,078
-20,475 Reduced 14.93%
116,704 $409,000
Q4 2022

Jan 10, 2023

BUY
$5.08 - $7.09 $40,640 - $56,720
8,000 Added 6.19%
137,179 $0
Q3 2022

Oct 11, 2022

BUY
$3.8 - $7.74 $92,891 - $189,204
24,445 Added 23.34%
129,179 $690,000
Q2 2022

Jul 11, 2022

BUY
$2.43 - $4.85 $81,978 - $163,619
33,736 Added 47.52%
104,734 $418,000
Q1 2022

Apr 07, 2022

BUY
$3.25 - $5.17 $230,743 - $367,059
70,998 New
70,998 $316,000
Q4 2021

Jan 07, 2022

SELL
$3.5 - $9.63 $518,252 - $1.43 Million
-148,072 Closed
0 $0
Q2 2020

Jul 07, 2020

BUY
$1.97 - $5.05 $28,143 - $72,144
14,286 Added 10.68%
148,072 $617,000
Q4 2019

Jan 13, 2020

BUY
$4.73 - $7.98 $165,289 - $278,861
34,945 Added 35.35%
133,786 $777,000
Q1 2019

Apr 05, 2019

BUY
$7.14 - $9.85 $62,517 - $86,246
8,756 Added 9.72%
98,841 $893,000
Q4 2018

Jan 08, 2019

BUY
$7.26 - $13.29 $162,086 - $296,712
22,326 Added 32.95%
90,085 $748,000
Q1 2018

Apr 19, 2018

BUY
$6.55 - $8.9 $62,329 - $84,692
9,516 Added 16.34%
67,759 $508,000
Q4 2017

Jan 24, 2018

BUY
$5.7 - $7.75 $56,145 - $76,337
9,850 Added 20.35%
58,243 $396,000
Q3 2017

Oct 06, 2017

BUY
$3.9 - $10.8 $188,732 - $522,644
48,393
48,393 $348,000

Others Institutions Holding ALDX

About Aldeyra Therapeutics, Inc.


  • Ticker ALDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,323,100
  • Market Cap $276M
  • Description
  • Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...
More about ALDX
Track This Portfolio

Track Woodstock Corp Portfolio

Follow Woodstock Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodstock Corp, based on Form 13F filings with the SEC.

News

Stay updated on Woodstock Corp with notifications on news.